Interpretation of advances in the treatment of non-small cell lung cancer at the 2025 World Conference on Lung Cancer (WCLC)
- VernacularTitle:2025年世界肺癌大会（WCLC）非小细胞肺癌治疗进展解读
- Author:
Bo BAO
1
,
2
;
Jiayu LU
1
;
Wen LIU
1
,
2
;
Xuxu ZHANG
2
;
Jiahe LI
2
;
Jipeng ZHANG
2
;
Wei LI
2
;
Qiang LU
2
Author Information
1. Basic Medical College, Air Force Medical University, Xi'an, 710032, P. R. China
2. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, 710038, P. R. China
- Publication Type:Journal Article
- Keywords:
World Conference on Lung Cancer;
non-small cell lung cancer;
targeted therapy;
immunotherapy;
epidermal growth factor receptor;
drug resistance;
antibody-drug conjugates;
interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(02):218-230
- CountryChina
- Language:Chinese
-
Abstract:
The 26th World Conference on Lung Cancer (WCLC) was held in Barcelona during September 6-9, 2025. As the world's largest and most influential academic meeting in the field of lung cancer, this year's congress unveiled long-term follow-up data from several pivotal studies and significant advances in novel therapeutic strategies. In the realm of targeted therapy, a next-generation combination strategy has been established as the new standard of care for the first-line treatment of patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), demonstrating a significant improvement in overall survival. In immunotherapy, novel combination regimens have not only addressed the therapeutic challenge of acquired resistance to EGFR targeted therapies, but also shown clear long-term survival benefits in both the perioperative and locally advanced settings. These findings pave the way for shifting the treatment paradigm to earlier stages for patients with NSCLC. Antibody-drug conjugates have made remarkable strides in this field. They have shown outstanding efficacy in patients with specific resistance mutations and those with brain metastases, and have also demonstrated immense potential in treating patients with HER2-aberrant lung cancer and broader NSCLC populations. This offers new therapeutic options for patients with refractory lung cancer.However, significant challenges remain, including the heterogeneity of resistance mechanisms, the selection of optimal treatment regimens, and management strategies for special populations. Future research should focus on identifying novel precision biomarkers and optimizing therapeutic strategies to ultimately improve clinical outcomes for all patients with lung cancer.
